ClinicalTrials.gg

Program

LY4395089

A development code.

In Eli Lilly's pipeline, FXR agonist. Its studies are mostly in Crohn Disease · Colitis, Ulcerative, led by Eli Lilly.

Furthest: phase 2, since Mar 16, 20263 company-led studies, 2 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly32 open or runningphase 2since Mar 16, 2026Mar 16, 2026Jun 2027phase 2 · NCT07483099
  • Named in Eli Lilly’s own pipeline as FXR Agonist + Mirikizumab, phase 2, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 16, 2026First studies: 2 phase 2 studiesFirst studyNCT07483099, NCT07483073
  2. May 12, 2026Phase 1 study in HealthyNCT07592572 · 14 enrolled · United States

Ahead

  1. Jun 2027Primary completion: phase 2 study in Crohn DiseaseNCT07483099
  2. Jun 2027Primary completion: phase 2 study in Colitis, UlcerativeNCT07483073

TargetBeta

“FXR agonist”the company's pipeline, read by Claude · source
“The main purpose of this study is to see how the safety and efficacy of a farnesoid X receptor (FXR) agonist (LY4395089), given together with mirikizumab compares with mirikizumab (alone) in adults with moderately to severely active Crohn's disease (CD).”study summary, read by Claude · the study

Other programs on NR1H4

ProgramCompanyFurthest phaseStudies
cilofexorruleGilead Sciencesphase 313

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07592572Healthy · United States1CompletedJul 8, 202614
NCT07483099Crohn Disease · United States, Belgium, Brazil and more2RecruitingJun 202760
NCT07483073Colitis, Ulcerative · United States, Belgium, Brazil and more2RecruitingJun 202760

How it is read

Names in the registry

  • “LY4395089”, 3 entries

Codes read as this program: LY4395089.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.